Agilent Technologies recently experienced a period of
price weakness, which analysts believe offers a
buying opportunity. Despite this, the
National Pension Service sold 267,543 shares of the company and other firms such as
First Horizon Advisors have also reduced their stakes.
Hahn Capital Management and
Proficio Capital Partners, however, have increased their holdings. The company's
Q1 earnings and revenues exceeded estimates, reporting Q1 sales of
US$1,681 million and an EPS beating forecasts by 4c. Despite robust Q1 results, the firm's stock fell due to a cautious FY25 view. Reflecting this cautious stance, the company lowered its price target to $159.00 and cut its revenue outlook due to dwindling demand. Nonetheless, there was strong performance in certain segments, with Life Sciences growing 4% while Applied Markets declined. In addition to presenting at the
TD Cowen Health Care Conference, Agilent is also slated to appear at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The company’s products are benefitting institutions like SFSU, which received cutting-edge Agilent technology for its new Science and Engineering Innovation Center.
Barclays has upgraded the company’s stock.
Agilent Technologies A News Analytics from Mon, 29 Jul 2024 07:00:00 GMT to Sat, 01 Mar 2025 20:53:52 GMT -
Rating 7
- Innovation -2
- Information 6
- Rumor -4
